相似文献
1
Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
J Thorac Dis. 2017 Sep;9(9):2847-2851. doi: 10.21037/jtd.2017.08.114.
2
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Clin Lung Cancer. 2017 Jul;18(4):e251-e258. doi: 10.1016/j.cllc.2016.11.015. Epub 2016 Dec 7.
3
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
BMC Res Notes. 2016 Mar 17;9:173. doi: 10.1186/s13104-016-1983-9.
4
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.
Mol Clin Oncol. 2017 Aug;7(2):295-297. doi: 10.3892/mco.2017.1310. Epub 2017 Jun 29.
5
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
J Thorac Oncol. 2017 Feb;12(2):390-396. doi: 10.1016/j.jtho.2016.07.022. Epub 2016 Aug 4.
6
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.
7
Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Clin Lung Cancer. 2019 Nov;20(6):e631-e637. doi: 10.1016/j.cllc.2019.06.013. Epub 2019 Jun 18.
8
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
J Pathol. 2017 Nov;243(3):307-319. doi: 10.1002/path.4950. Epub 2017 Sep 28.
9
Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Clin Lung Cancer. 2019 Sep;20(5):339-349. doi: 10.1016/j.cllc.2019.05.006. Epub 2019 May 11.
10
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
Adv Exp Med Biol. 2016;893:179-187. doi: 10.1007/978-3-319-24223-1_9.
引用本文的文献
1
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.
J Clin Med. 2018 Jun 15;7(6):153. doi: 10.3390/jcm7060153.
本文引用的文献
1
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.
2
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
3
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
4
Efficacy of crizotinib in fusion variants.
J Thorac Dis. 2016 Oct;8(10):E1381-E1383. doi: 10.21037/jtd.2016.10.62.
5
W'ALK' Into the Next Stage.
Clin Lung Cancer. 2017 Mar;18(2):122-126. doi: 10.1016/j.cllc.2016.10.005. Epub 2016 Oct 26.
6
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Clin Cancer Res. 2016 Nov 15;22(22):5527-5538. doi: 10.1158/1078-0432.CCR-16-0569. Epub 2016 Oct 25.
7
Ceritinib: a Review in ALK-Positive Advanced NSCLC.
Target Oncol. 2016 Oct;11(5):693-700. doi: 10.1007/s11523-016-0460-7.
8
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
J Thorac Oncol. 2017 Feb;12(2):390-396. doi: 10.1016/j.jtho.2016.07.022. Epub 2016 Aug 4.
9
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18.
10
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11.
Zotero 插件